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Abstract
iron overload in β-thalassemia major occurs mainly due to blood transfusion, an essential treatment 
for β-thalassemia major patients, which results in oxidative stress. it has been thought that oxidative 
stress causes elevation of immune system senescent cells. under this condition, cells normally enhance 
in aging, which is referred to as premature immunosenescence. Because there is no animal model 
for immunosenescence, most knowledge on the immunosenescence pattern is based on induction of 
immunosenescence. in this review, we describe iron overload and oxidative stress in β-thalassemia 
major patients and how they make these patients a suitable human model for immunosenescence. We 
also consider oxidative stress in some kinds of chronic virus infections, which induce changes in the 
immune system similar to β-thalassemia major. in conclusion, a therapeutic approach used to improve 
the immune system in such chronic virus diseases, may change the immunosenescence state and make 
life conditions better for β-thalassemia major patients.
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Introduction
In spite of considerable progress in iron chelating agents, 
iron overload is still the major cause of death in β-thalassemia 
major patients [1]. In addition to blood transfusion, other rea-
sons for iron overload are further iron absorption from the 
gastrointestinal tract in β-thalassemia major patients and he-
molysis. Excessive iron deposits in visceral organs (mainly in 
the heart) lead to tissue damage, and organ dysfunction and 
failure such as cardiac disease, which is the major cause of 
death in β-thalassemia major patients [2]. In normal condi-
tions, iron transport in the cells is managed by iron-responsive 
proteins [3]. Actually, nonheme iron is circulating and is/in 
a form bound to transferrin that is sensed and internalized 
by the transferrin receptor (TfR) on the cell surface. TfR 
is expressed by all iron requiring cells. In an iron overload 
state, free Fe may exceed iron-binding capacity of transferrin, 
which leads to unrestrained circulating forms of non-transfer-
rin bound iron (NTBI) [4, 5]. NTBI is a potentially toxic form 
of iron as labile iron which transmits into cytosol in a non-reg-
ular procedure. It deposits on cell surfaces and/or is excessive-
ly taken up by cells in the forms that lead to raising the labile 
cell iron (LCI). LCI is cell-infiltrating forms of iron which are 
redox active [6]. Non-transferrin bound iron and transferrin 
bound iron move to cytosol, but there are no cellular moni-
tored processes for Fe excretion [7]. Better understanding of 
the mechanism of the immune system in an excessive iron 
condition in β-thalassemia major patients and immunological 
common points between thalassemia and other diseases can 
increase our knowledge of the immune system behavior in 
oxidative stress condition. Thus, in the present review, we 
will discuss the effect of iron overload and oxidative stress 
conditions on the immune system and then immunological 
function similarities among aging, chronic virus infection and 
β-thalassemia major diseases in humans.
Thalassemia and oxidative stress
Accumulation of plasma NTBI in β-thalassemia major 
correlates with an increase in oxidation products and de-
crease in antioxidant capacity [8]. Iron is the most abun-
dant transition metal in the periodic table with oxidation 
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states ranging from −II to +VI. Iron has two biologically 
relevant oxidation states, Fe2+ and Fe3+, and electron trans-
fer between Fe2+ and Fe3+. Fe has a vital function in the 
respiratory chain because of Fe oxidation state, Fe2+ can be 
easily oxidized to Fe3+ and reduced back and is involved 
in essential energy production by many living organisms 
specially aerobic cells [9]. The redox potential of iron is the 
main reason for its toxicity. Fe can lead to the Haber Weiss 
Fenton pattern by engendering the reactive oxygen species 
(ROS). Fe2+ reduces one electron of dioxygen and leads to 
superoxide formation, specially hydroxyl radicals [2].
Fe2+ + O2– → Fe3+ + O2–•
2O2−• + 2H+ → H
2
O
2
 + O
2
Fe2+ + H
2
O
2
 → OH• + OH– + Fe3+
Also Fe2+ can catalyze hydrogen peroxide (H
2
O
2
) and 
generate hydroxyl radical, which is the most reactive and 
damaging intermediate of cellular metabolism. In fact, 
Fe is an intrinsic producer of ROS [10]. There are many 
reasons for iron overload in β-thalassemia major patients 
such as macrophage recycling of iron from hemoglobin, 
excessive iron intake, genetic defect and hemolysis of re-
peated blood transfusions. Iron overload leads to a rise in 
LCI and promotes formation of ROS from physiological 
oxygen intermediates [5, 11, 12]. Indeed enhanced pro-
duction of ROS increases oxidants/antioxidants activity 
balance like β-thalassemia major conditions and disturbs 
the balance between ROS production and ROS removal, 
which is called oxidative stress [13]. Certainly, one ob-
vious reason for oxidative stress in β-thalassemia major 
is iron overload and the other one is excessive unpaired 
α-hemoglobin chains [14]. It has been found that accumu-
lation and autoxidation of the unpaired α-globin chains in 
severe β-thalassemia major would generate ROS, super-
oxide (O2−) and H
2
O
2
 that damage cellular proteins, lipids, 
and nucleic acids. Indeed, free α chains in β-thalassemia 
increase autoxidation rates by about twice faster [15, 16].
Oxidative stress and immunosenescence
The general consensus in iron overload condition is 
cell cycle progression, an elevated physiological level of 
ROS and oxidative stress condition for a prolonged period, 
which lead to cell death or cell cycle arrest (senescence) 
much earlier than the expected Hayflick limit, which has 
been termed premature senescence [17]. The Hayflick limit 
is an occurrence that labels potential numbers of prolifer-
ation in diploid cells. It has been found that the shortening 
of telomeres happens in somatic cells with each cell divi-
sion. Indeed, human somatic cells have limited replicated 
life duration because telomere erosion leads eventually to 
cell cycle arrest, aging/senescence, or apoptosis [18, 19].
Many studies have described the variations that occur 
in senescence cells by oxidative stress condition, including 
phosphorylation at Ser51 of eIF2α, which plays a major 
role in translation repression, or damaging cellular com-
ponents such as DNA, chromatin structure, proteins and 
lipids [20-22]. The preferential mechanism underlying 
this aging is DNA damage, which specially accelerates 
the telomere-shortening rate in oxidative stress condition 
[23-25]. Actually, some kinds of DNA damage, which do 
not repair, lead to cellular senescence or cell death, consis-
tent with the findings that DNA repair capacity related to 
oxidative DNA damage significant downturn in senescent 
cells [23]. Early inception of cellular senescence, which 
is caused by oxidative stresses, is termed stress-induced 
premature senescence (SIPS) [26]. H
2
O
2
 has been the 
most routinely used inducer of SIPS [27]. Enhancement of 
H
2
O
2
 induces remarkable telomere shortening and DNA 
damaging and also leads to cell cycle arrest due to p53-de-
pendent pathway. Indeed, H
2
O
2
 enhances p53 binding ac-
tivity while the DNA repair capacity does not increase [28, 
29]. Circulating iron causes oxidative damage to lympho-
cyte DNA and has a negative effect on antioxidant defense. 
Also, it adversely affects immune cell proliferation and 
function [30, 31]. Like other mitotic cells, T lymphocytes 
are unable to proliferate when they reach to replicative 
senescence and gain some functional phenotypes instead 
[32]. One of the well-known markers of senescence T cells 
is lack of expression of CD28, the major co-stimulatory re-
ceptor. Cell cycle arrest and inexistence of cell surface and 
mRNA expression of the CD28 co-stimulatory molecule 
on T cells have been seen after repeated cell cycles and 
several rounds of cell division [33]. Replicative senescence 
of CD8 T cells is also resistant to programmed cell death 
and a similar finding has been reported for senescent fi-
broblasts, and permanently loses expression of the CD28 
marker [34, 35]. There is a correlation between CD28 and 
telomerase; the shorter telomeres have been seen in CD28– 
T cells compared with CD28+ T cells. Indeed, T cells are 
able to upregulate telomerase during activation and opti-
mal telomerase upregulation in T cells is highly dependent 
on CD28 signal transduction [36-38]. Telomerase activi-
ty requires human telomerase catalytic subunit (hTERT) 
phosphorylation. TERT is a substrate for Akt in T cells, so 
the loss of CD28 leads to a decline in Akt phosphorylation, 
consequently senescence T cells differentiate from CD28+ 
to CD28–, which could not be reversed [39, 40]. Besides, 
hTERT and AKT, and mitogen activated protein kinases 
have a principal role in upregulation of telomerase activity 
in T cells [41]. Interestingly, telomerase activity in CD4+ 
T cells is much more than in CD8+ T cells, which could be 
the main reason for increasing T CD8+28– in aging [38]. 
Gharagozloo et al. studies on peripheral blood from β-thal-
assemia major patients have shown an increased level of 
premature senescence of T lymphocytes, T CD8+28– [42], 
which may be related to the oxidative stress condition of 
thalassemia. Moreover, a decrease in CD4+ cell circulation 
and expansion of CD8+28– in peripheral blood of thalas-
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semia patients have been shown [43]. There are three main 
relevant proofs for shifting lymphocytes to the senescence 
state in β-thalassemia major: 
1.  TfR1 plays essential roles in lymphocyte development 
and activation. Expression of TfR downregulates in iron 
overload state due to coordination of messenger RNA-en-
coding proteins by iron regulatory proteins. Similarly, 
blockade of TfR expression inhibits entry of T cells into 
the S phase of the cell cycle and abrogates DNA synthesis. 
Also, inhibition of TfR expression in T cells prevents 
cell cycle progression from G1 to S phase [5, 44].
2.  Synthesis of ferritin, the main storage protein of iron, 
increases in iron overload condition and oxidizes in 
oxidative stress state and breaks down by proteasome, 
which cause liberation and enhancement of iron. Satura-
tion of ferritin and presence of transferrin-bound iron are 
associated with enhanced iron uptake by lymphocytes, 
which inhibits proliferation of lymphocytes [44-46].
3.  A high level of ROS for a prolonged period disturbs the 
cell cycle progression of most cells, which could be an 
explanation for proliferation arrest of T lymphocytes [47].
Iron overload also leads to natural killer (NK) cell dys-
function, impaired neutrophil cytotoxicity, changes in the 
ratio of CD4+ to CD8+ lymphocytes, impairs proliferative 
responses of helper and cytotoxic T cells and also affects 
MHC class II and intercellular adhesion molecule 1 [48, 
49]. Furthermore, iron overload is associated with reduced 
phagocytic activity toward some fungi, such as Candida 
albicans and may also promote the growth of hepatitis 
C virus [50]. Therefore, iron overload and oxidative stress 
condition in β-thalassemia major may result in an impaired 
immune function.
Characteristics of immunosenescence  
and immunological aging
As outlined above, oxidative stress in β-thalassemia 
major has some effect on the immune system which in-
creases T CD8+28– replicative senescence T-lymphocyte. 
Identical clonal population of CD28– T cells has shorter 
telomeres than other CD28+ T cells [36]. One obvious 
culprit is oxidative stress condition which can be a reason 
for DNA damage and telomerase shortening [51]. Simi-
lar to oxidative stress, prolonged activation of T cells, in 
chronic infections, and aging increase T-cells replicative 
senescence or in other words, increase T-cells with a dif-
ferent function and proliferation inability. As mentioned 
before, senescence lymphocyte has been known by the 
loss of the CD28 marker, a well-known co-stimulatory 
molecule which serves as a marker for CD8 T-cells rep-
licative senescence. CD28 has major roles during T-cells 
activation, proliferation and survival [52, 53]. Besides the 
function and proliferation, CD8+ T cells that lose expres-
sion of CD28, display several peculiar features including 
reduction in T-cells receptor diversity [54], suppressive 
effect on CD4 T cells activation and defective prolifera-
tion during antigen stimulation [55]. Normal CD8+ T cells 
have an essential role in the protective effects of T helper 
cells vaccination and are very effective in T helper cells 
responsiveness and activation; T CD8+28– cells reduce im-
mune response to pathogens, new infections, viruses and T 
cell vaccines [54]. Expression of inhibitory killer immuno-
globulin-like receptors of NK cells on T CD8+28– cells can 
have inhibitory effects [56]. T CD8+28– cells have a reg-
ulatory role in adaptive immunity, they convert dendritic 
cells (DCs) to tolerogen by decreasing the expression of 
the co-stimulatory molecule on DCs [57]. Another inhibi-
tory factor of senescence T cell is TGF-β, a cytokine that 
has a regulatory effect on the immune system. Besides the 
inhibitory effects of T CD8+28– cells on T helper lympho-
cytes, presence of these cells can decrease production of 
the antibody [58]. Although, by the age of 80 and above, 
50-60% of CD8+ T cells lack CD28 expression [35], a high 
proportion of T CD8+28– cells have been observed in some 
chronic viral infections such as HIV, cytomegalovirus and 
Epstein-Barr virus (EBV). T CD8+28– cells specific for 
the virus increase in these patients [59] (Fig. 1), suggest-
ing that chronic stimulation of the immune system pref-
erentially induces a kind of immune inhibitory state or 
immunosenescence. T CD8+28– cells are observed in old 
age humans and non-human primates but not in mice [56], 
so mice cannot be a model for old age human immune 
system with elevated T CD8+28– cells. Presence of CD28– 
T cells can be the reason for lower capacity to respond 
to new infections, environmental exposures, and vaccines 
in old ages [54, 60]. It seems that augmentation of senes-
cence T cells impairs the immune system function, and 
an increase in these cells in β-thalassemia major patients 
may explain an increased incidence of infections. Indeed, 
infection is directly responsible for 12-46% of morbidity 
in patients with β-thalassemia major [61]. Presence of se-
nescence cells could have inhibitory effects on the immune 
system. In particular, they can compete for access to the 
antigen. Overall, the mechanism of action and their effects 
on the immune system has been poorly understood.
Common points of chronic virus infection 
and thalassemia
Human immunodeficiency virus increases intracellular 
free radicals by permanent activation and consequently, 
elevates markers of oxidative stress condition such as ox-
idized lipids, proteins, and DNA and reduces antioxidant. 
Besides permanent cell activation, virus proteins such as 
tat and GP120 cause oxidative stress and increase ROS 
production [62]. Also, it seems that HAART treatment has 
a pro-oxidant effect and promotes oxidative stress condi-
tion. Oxidative stress in HIV-positive patients increases 
virus replication and decreases antioxidant activity [63, 
64]. Many studies have reported lack of antioxidants in 
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acquired immunodeficiency syndrome (AIDS) patients, 
which could be the reason for drug toxicity and deleteri-
ous effects on the immune system [65]. It seems that ROS 
production in oxidative stress condition in HIV infected in-
dividuals, remarkably decreases antioxidant enzymes and 
causes progression to AIDS [63, 66]. Like β-thalassemia 
major, oxidative stress impairs phagocytic functions and 
enhances senescence T lymphocytes, T CD8+28– cells, in 
HIV-infected adults and children [67]. As it is expected, 
there is a positive correlation between T CD8+28– cells 
and rapid progression of the disease. Irrespective of the 
CD4 T cells number, HIV disease progresses faster to 
AIDS in aging people [68, 69], which could be due to the 
increment senescence T cells in aging. Oxidative stress 
also occurs in chronic liver disease. Hepatitis C virus 
(HCV) contains core proteins and non-structural proteins, 
which cause oxidative stress. Oxidative stress markers 
such as ROS, oxidized lipid and serum hydroperoxides in-
crease in hepatitis C. Also the antioxidants level decreases 
in liver and blood of HCV infected individuals. Similar to 
thalassemia, iron overload has been found in this disease 
and severe hepatitis and fibrosis correlate with the serum 
iron level [70-72]. With regard to the oxidative stress, ROS 
marker levels significantly increase in HCV patients in 
comparison with normal controls [73]. Mitochondria and 
cytochrome P450 enzymes of Kupffer cells and neutro-
phils produce ROS in hepatocytes in acute or chronic liver 
disease [74]. In addition to the ROS, low levels of hTERT 
mRNA expression have been shown in chronic viral hep-
atitis [75]. In HCV infected individuals, ROS increase in 
lymphocytes of patients is remarkable. Also, enhanced 
senescence T CD8+28– has been found in chronic hepa-
titis C condition [76, 77]. EBV is the major agent in the 
pathogenesis of a variety of lymphomas. EBV products 
include six EBV nuclear antigens (EBNA1, 2, 3A, 3B, 3C 
and LP), three latent membrane proteins (LMP1, 2A, 2B), 
two non-translated RNAs (EBER1 and EBER2) and sever-
al microRNAs. EBNA1 is common in all EBV-associated 
malignancies and cause telomere uncapping, is a common 
cause of DNA damage at telomeres, and DNA breakage 
at telomeres [78-80]. T CD8+ cells specific for EBV have 
shorter telomeres than other T cells and senescence CD8+ 
T cells also increase in EBV infected individuals [81, 82]. 
These data are consistent with previous studies indicating 
chronic EBV infection drives EBV specific CD8 T cells 
towards differentiated phenotypes.
virus
T cell
ROS
Fe
ageing
Shift immune response 
Inhibit vaccination  
Infection increase 
Increase cancer
...
CD8
senescence 
T cell
CD3
CD28
↑ TNF-α
Fig. 1. Main reasons for generation of senescence cells, which result in immune dysfunction chronic infection and iron 
overload affect immune system CD8+ lymphocytes similar to aging. They cause senescence lymphocytes increase that lack 
CD28 marker. Senescence lymphocytes and ROS increase TNF-α production. TNF-α affect CD8+ lymphocytes and increase 
senescence cells, a positive feedback loop. Senescence cells shift immune response and adversely affect immune system
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Oxidative stress and tumor necrosis factor α
Oxidative stress increases tumor necrosis factor α 
(TNF-α) via nuclear factor κB (NF-κB) activation, sub-
ject of an excellent review (Fig. 1). Indeed, ROS releases 
IκB, an inhibitory factor of NF-κB, and activates NF-κB 
to translocate into the nucleus. Oxidative stress and TNF-α 
are induced by HIV-1 tat [83] and TNF-α can also induce 
HIV expression in monocytic cells. TNF-α induces a sig-
nificant quantitative reduction in CD28 molecules on the 
cell surface which leads to the genesis of CD28– T cells. 
Besides ROS, senescence cells increase production of 
proinflammatory cytokines such as TNF-α [84, 85]. Sur-
prisingly, TNF-α increases in HIV, EBV, HCV and β-thal-
assemia major patients and an elevated level of TNF-α 
provokes a decreased expression of CD28 [86-89].
Antioxidant therapy in chronic virus 
infection and β-thalassemia major
Natural antioxidant
Glutathione (GSH) is the major thiol (non-enzymatic) 
intracellular antioxidant which decreases in oxidative 
stress condition [90]. GSH synthesis is repressed in HIV 
infection. Generation of ROS in HIV-infected individuals 
results in disruption in GSH metabolism [91]. Non-enzy-
matic antioxidants such as GSH, vitamins C, E and A, and 
activity of enzymatic antioxidants such as catalase, super-
oxide dismutase (SOD), GSH peroxidase (GPx) and GSH 
s-transferase, considerably decrease in HIV/AIDS [92]. 
Also, formation of ROS results in decreasing CD4 counts 
in HIV patients. Gamma glutamyl transferase is the major 
enzyme for GSH metabolism in cells [93]. GPx is a sele-
nocysteine enzyme which protects cells from endogenous 
peroxides, modulates the respiratory burst and reduces su-
peroxide production. Decreasing GSH by 10% to 40% in 
lymphocytes can completely inhibit activation and GSH 
depletion adversely affects immunological functions and 
viral clearance [94]. It seems that oxidative stress is the ma-
jor mechanism in the progression of HIV [95]. Therefore, 
antioxidant agents can bring back the immune function and 
slow the progression to AIDS [96]. GSH also inhibits NF-
κB by scavenging free radicals within the cytosol [90]. The 
level of GSH in peripheral blood mononuclear cells (PB-
MCs) of thalassemia major patients is very low. Restoration 
of GSH levels could increase PBMC proliferation [97].
Selenium
Selenium is an essential element for biosynthesis of 
GSH contents. Selenium deficiency has an adverse effect 
on cellular and humoral immunity. Selenium with other 
antioxidants such as vitamin E is more involved in pre-
venting free radicals production. Selenium compounds 
reduce oxidative damage to biomolecules such as DNA 
and scavenge free radicals, and repair molecular damage 
sites [98]. Lack of selenium is related to a decrease in GSH 
peroxidase activity in HIV-infected individuals which un-
derlies tissue injury by ROS. In HIV, alterations of antiox-
idant enzymes due to oxidative stress decrease antioxidant 
defense. Thus, accumulation of selenium can potentiate 
some antioxidant enzymes’ effect against free radicals and 
inhibit HIV replication [99]. Selenium deficiency results 
in faster progression of the disease in HIV patients [64]. 
Selenium seems to be a crucial nutrient for HIV-infected 
individuals and is a potent inhibitor of HIV replication in 
vitro [100]. Also, a progressive decline in plasma selenium 
has been associated with persistent loss of CD4 T cells in 
HIV infection [101]. Selenium-deficiency is indicative of 
a poor prognosis in HIV-positive patients. They are nearly 
20 times more susceptible to die from HIV-related causes 
[102]. Indeed, a lower level of selenium in HIV-infected 
patients decrease the numbers and functions of circulating 
CD4+ T cells profoundly [103]. Selenium also has a pro-
tective role in individuals infected with HCV against the 
progression to cancer [104].
Zinc
Zinc (Zn) deficiency adversely affects the immunolog-
ical function. It causes an imbalance between Th1 and Th2 
functions, cytokine production and decreases T cells counts 
[105]. Zn is an antioxidant that can restore immune func-
tions and increase CD4+ T cells count in AIDS and inhibit 
the incidence of opportunistic infections in AIDS patients. 
It increases neutrophil functions and cytokine production 
(IL-1, IL-6, TNF-α, IFN-α) in PBMCs [106]. HCV-induced 
oxidative stress increases oxidized GSH [107]. Also, GSH 
production increases PBMCs [108] but levels of vitamins C, 
B, and E and activity of SOD and catalase and SOD are low 
in HCV infected individuals [109, 110]. Zn is involved in 
SODs and enzymes and protects from lipid peroxidation. Zn 
has a synergistic effect with other antioxidants. Zn supple-
ments significantly improve the liver function [111].
Vitamins
Vitamin E acts as an antioxidant on biomembranes 
and prevents lipid peroxidation more effectively than 
selenium. Actually, selenium has the major role for 
scavenging free radicals. Vitamin E is the principal lipid 
soluble, chain breaking antioxidant in mitochondria, mi-
crosomes, and lipoproteins. Vitamin E can reduce ROS in 
lymphocytes of β-thalassemia patients [112]. Vitamin C 
is a water soluble vitamin which neutralizes water soluble 
radicals and protects cell components from free radical 
damage and reduces lipid peroxidation derivatives [113]. 
HIV-infected individuals have a low level of vitamins C 
and E, which may be due to oxidative stress which in-
creases demand in the detoxification/neutralization of free 
radicals or malabsorption and diarrhea that are common 
complications of AIDS [63]. Remarkably, levels of vita-
mins A, C and E, especially vitamin E, in HIV-positive 
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adult or pediatric patients are low [114-116]. Vitamin E 
also inhibits H
2
O
2
 production in EBV infection [117]. Vi-
tamin A deficiency has been shown to induce oxidative 
stress [118]. Oxidative stress and a lower level of antiox-
idant agents have also been seen in pediatric patients with 
acute hepatitis A [119, 120]. Concentrations of vitamin E 
and Zn and levels of antioxidant enzymes GPx and SOD 
are significantly low in β-thalassemia patients. Antiox-
idants like silymarin, a flavonolignan complex isolated 
from milk thistle, can boost the immune system function 
and also decrease TNF-α in these patients [121, 122]. 
Maybe, antioxidant supplements normalize the immune 
dysfunction in oxidative stress condition [123, 124].
Conclusions
A survey of the immune system of old age is really nec-
essary for vaccination of old ages, and age related diseases, 
which is one of the greatest government problems. Howev-
er, oxidative stress is responsible for many old age related 
diseases [125-127]. In addition, air pollutants, modern life 
style and diet have made immune system senescence fast-
er than in the past; however, there is a strong correlation 
between cancer and immunosenescence. Oxidative stress 
could be a reason for old age diseases such as Alzheimer’s 
disease and Parkinson’s disease and has an important role 
in autoimmune diseases such as systemic lupus erythema-
tous [128, 129]. Besides, because of chronic iron overload 
in thalassemia major patients, chronic oxidative stress can 
be the reason for immunosenescence. Physiologic condi-
tions of these patients can make them a human model for 
immunosenescence. Also, iron overload occurs in other 
diseases such as haemodialysed (HD) uremic patients, who 
receive iron intravenously. HD patients have defects in 
NK and T cell division and function. Immunosenescence 
features have been poorly understood. Therapeutic inter-
ventions which change senescence cell behavior are very 
useful for treatment in age related diseases, chronic virus 
infections and any conditions that increase these cells. Anti- 
oxidant therapy can be really effective for the immune 
system function in oxidative stress conditions. Selective 
elimination of these cells represents a new way to improve 
the immune system. It will reveal strategies to boost the 
immune system. A study of the immune system in thal-
assemia patients may identify more characteristics of the 
immune system senescence cells. It may also explain why 
the elevated level of NTBI increases the risk of bacterial 
and fungal infections and rapid leukemic progression more 
specifically. In addition, further studies need to define the 
phenotypic character of senescence lymphocyte such as the 
amount of P53, telomere length, DNA damage percentage, 
levels of the ROS and expression of surface markers includ-
ing CD57 and CD100 in thalassemia patients. Because of 
the chronic oxidative state in these patients, investigation 
of old age diseases relevant to the immune system can be 
useful. In conclusion, understanding the immune system of 
thalassemia patients can increase our knowledge of aging, 
vaccination of old age and changes in the immune system, 
which also occur in chronic virus infections. Also, it may 
promote new insights for improving the quality of life of ma-
jor thalassemia patients through developing new therapies.
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